Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease

Hormones

Volumn 12, Issue 4, 2013, Pages 483-494

  Nogueira, Cláudia ^a,b   Souto, Selma B ^c   Vinha, Eduardo ^a   Carvalho Braga, Daniel ^a,b   Carvalho, Davide ^a,b  

^a Centro Hospitalier de Sao Joao   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE BRAGA   (Portugal)

Author keywords

Chronic kidney disease; Oral glucose lowering drugs; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BROMOCRIPTINE; CREATININE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR 40 AGONIST; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; LINAGLIPTIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL DISTENSION; ABSENCE OF SIDE EFFECTS; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIARRHEA; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER DISEASE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; COMORBIDITY; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84891498518     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1436     Document Type: Review

References (80)

1. Souto SB, Souto EB, Braga DC, Medina JL, 2011 Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Eur J Clin Pharmacol 67: 653-661.
2. Packham DK, Alves TP, Dwyer JP, et al, 2012 Relative incidence of eSrD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the Diametric (Diabetes Mellitus Treatment for renal insufficiency Consortium) database. Am J Kidney Dis 59: 75-83.
3. Garg R, Williams ME, 2013 Diabetes management in the kidney patient. Med Clin North am 97: 135-156.
4. National Kidney Foundation, 2012 Kdoqi Clinical Practice guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 60: 850-886.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al, 2012 Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the american Diabetes association (ADA) and the European association for the Study of Diabetes (eaSD). Diabetologia 55: 1577-1596.
6. Graham GG, Punt J, Arora M, et al, 2011 Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50: 81-98.
7. UK Prospective Diabetes Study (Ukpds) group, 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (Ukpds 34). Lancet 352: 854-865.
8. Lamanna C, Monami M, Marchionni N, Mannucci E, 2011 Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes obes Metab 13: 221-228.
9. Lalau JD, 2010 Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 33: 727-740.
10. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE, 2010 Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 14: CD002967.
11. Sambol NC, Chiang J, Lin ET, et al, 1995 Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 35: 1094-1102.
12. Sibal L, Home PD, 2009 Management of type 2 diabetes: NiCe guidelines. Clin Med 9: 353-357.
13. Ekstrom N, Schioler L, Svensson AM, et al, 2012 Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes register. BMJ open: 2(4)pii: e001076.
14. Arroyo D, Melero R, Panizo N, et al, 2011 Metformin-associated acute kidney injury and lactic acidosis. Int J Nephrol 2011: 749653.
15. Bryan J, Crane A, Vila-Carriles WH, Babenko AP, Aguilar-Bryan L, 2005 Insulin secretagogues, sulfo-nylurea receptors and K(aTP) channels. Curr Pharm Des 11: 2699-2716.
16. Shank WA Jr, Morrison AD, 1986 Oral sulfonylureas for the treatment of type ii diabetes: an update. South Med J 79: 337-343.
17. Jonsson A, Rydberg T, Sterner G, Melander A, 1998 Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53: 429-435.
18. Groop LC, 1992 Sulfonylureas in NiDDM. Diabetes Care 15: 737-754.
19. Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J, 1973 Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 331-338.
20. Charpentier G, Riveline JP, Varroud-Vial M, 2000 Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 26: Suppl 4: 73-85.
21. Palmer KJ, Brogden RN, 1993 Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 46: 92-125.
22. Drouin P, Standl E, 2004 Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes obes Metab 6: 414-421.
23. Langtry HD, Balfour JA, 1998 Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 55: 563-584.
24. Landgraf R, 2000 Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs aging 17: 411-425.
25. Malaisse WJ, 2003 Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat endocrinol 2: 401-414.
26. McLeod JF, 2004 Clinical pharmacokinetics of nateg-linide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 43: 97-120.
27. Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pe-cher E, 2007 Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes obes Metab 9: 506-511.
28. Inoue T, Shibahara N, Miyagawa K, et al, 2003 Pharma-cokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 60: 90-95.
29. Devineni D, Walter YH, Smith HT, et al, 2003 Pharma-cokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 43: 163-170.Available at urL: http://www.accessdata.fda.gov/drug-satfda_docs/label/2011/021204s014lbl.pdf (accessed 06/09/2013).
30. Del Prato S, Heine RJ, Keilson L, et al, 2003 Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 26: 2075-2080.
31. Culy CR, Jarvis B, 2001 Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus. Drugs 61: 1625-1660.
32. Scott LJ, 2012 Repaglinide: A review of its use in type 2 diabetes mellitus. Drugs 72: 249-272.
33. Schumacher S, Abbasi I, Weise D, et al, 2001 Single-and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57: 147-152.
34. Lehmann JM, Moore LB, Smith-oliver TA, et al, 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPar gamma). J Biol Chem 270: 12953-12956.
35. Gillies PS, Dunn CJ, 2000 Pioglitazone. Drugs 60: 333-345.
36. Budde K, Neumayer HH, Fritsche L, et al, 2003 The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55: 368-374.
37. Abe M, Kikuchi F, okada K, Kaizu K, Matsumoto K, 2008 Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis. Diabetes res Clin Pract 80: 432-438.
38. Abe M, Kikuchi F, Okada K, Matsumoto K, 2009 Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis. Ther apher Dial 13: 238-239.
39. Beltowski J, Rachanczyk J, Wlodarczyk M, 2013 Thia-zolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPar Res 2013: 628628.
40. Available at URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf (accessed 06-09-2013).
41. Azoulay L, Yin H, Filion KB, et al, 2012 The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344: e3645.
42. Clissold SP, Edwards C, 1988 Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35: 214-243.
43. Mertes G, 2001 Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes res Clin Pract 52: 193-204.
44. Neuser D, Benson A, Bruckner A, et al, 2005 Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug investig 25: 579-587.
45. Segal P, Eliahou HE, Petzinna D, et al, 2005 Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clin Drug investig 25: 589-595.
46. Available at URL: http://www.accessdata.fda.gov/drug-satfda_docs/label/2012/020482s025lbl.pdf (accessed 10-08-2012).
47. Available at URL: http://www.accessdata.fda.gov/drug-satfda_docs/label/2012/020682s010lbl.pdf (accessed 23-08-2012).
48. Nauck MA, 2011 Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124: S3-18.
49. Baetta R, Corsini A, 2011 Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 71: 1441-1467.
50. Duckworth W, abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldeman S., McCarren M, Vitek ME, Henderson WG, Huang GD, Vai DT Investigators., 2009 Glucose control and vascular complications in veterans with type 2 diabetes. N engl J Med 360: 129-139.
51. Andersson C, van Gaal L, Caterson ID, et al, 2012 Relationship between Hba1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 55: 2348-2355.
52. Deacon CF, 2011 Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes obes Metab 13: 7-18.
53. Bergman AJ, Cote J, Yi B, et al, 2007 effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30: 1862-1864.
54. Chan JC, Scott R, Arjona Ferreira JC, et al, 2008 Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes obes Metab 10: 545-555.
55. Scheen AJ, 2010 Pharmacokinetics of dipeptidylpepti-dase-4 inhibitors. Diabetes obes Metab 12: 648-658.
56. He H, Tran P, Yin H, et al, 2009 Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 37: 536-544.
57. Scheen AJ, 2012 DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 38: 89-101.
58. Lukashevich V, Schweizer A, Shao Q, groop PH, Kothny W, 2011 Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes obes Metab 13: 947-954.
59. Ito M, Abe M, Okada K, et al, 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 58: 979-987.
60. Dhillon S, Weber J, 2009 Saxagliptin. Drugs 69: 2103-2114.
61. Boulton DW, Li L, Frevert EU, et al, 2011 Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 50: 253-265.
62. Nowicki M, Rychlik I, Haller H, et al, 2011 Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxa-gliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 65: 1230-1239.
63. Scirica BM, Bhatt DL, Braunwald E, et al, 2013 Saxa-gliptin and Cardiovascular outcomes in Patients with Type 2 Diabetes Mellitus. N engl J Med 369: 1317-1326.
64. Scott LJ, 2010 Alogliptin: A review of its use in the management of type 2 diabetes mellitus. Drugs 70: 2051-2072.
65. Graefe-Mody U, Friedrich C, Port A, et al, 2011 Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes obes Metab 13: 939-946.
66. Valiquette G, 2011 Bromocriptine for diabetes mellitus type ii. Cardiol rev 19: 272-275.
67. Available at URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf (accessed 06-09-2013).
68. Mejia-Rodriguez O, Herrera-Abarca JE, Ceballos-Reyes G, et al, 2013 Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease. Biomed res int 2013: 104059.
69. Hummel CS, Lu C, Loo DD, et al, 2011 Glucose transport by human renal Na+/D-glucose cotransporters SgLT1 and SgLT2. Am J Physiol Cell Physiol 300: C14-21.
70. Wright EM, 2001 Renal Na(+)-glucose cotransporters. Am J Physiol renal Physiol 280: F10-18.
71. Nair S, Wilding JP, 2010 Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin endocrinol Metab 95: 34-42.
72. Kim Y, Babu AR, 2012 Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr obes 5: 313-327.
73. Komoroski B, Vachharajani N, Boulton D, et al, 2009 Dapagliflozin, a novel SgLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85: 520-526.
74. Vasilakou D, Karagiannis T, Athanasiadou E, et al, 2013 Sodium-glucose Cotransporter 2 inhibitors for Type 2 Diabetes: a Systematic review and Meta-analysis. Ann intern Med 159: 262-274.
75. Available at urL: http://clinicaltrials.gov/ct2/show/NCT00663260 (accessed 04-06-2013).
76. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF, 2010 Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223-2233.
77. Kebede MA, Alquier T, Latour MG, Poitout V, 2009 Lipid receptors and islet function: therapeutic implications? Diabetes obes Metab 11: Suppl 4: 10-20.
78. Rayasam GV, Tulasi VK, Davis JA, Bansal VS, 2007 Fatty acid receptors as new therapeutic targets for diabetes. Expert opin Ther Targets 11: 661-671.
79. Araki T, Hirayama M, Hiroi S, Kaku K, 2012 Gpr40-induced insulin secretion by the novel agonist TaK-875: first clinical findings in patients with type 2 diabetes. Diabetes obes Metab 14: 271-278.
80. Leifke E, Naik H, Wu J, et al, 2012 A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel gPr40 agonist, TaK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 92: 29-39.